Dive into the archives.


  • LATE BREAKING: New Phase III Data for Cladribine to be Presented at AAN

    CLARITY (CLAdRIbine tablets Treating MS OrallY) Study Data to be Presented as Late-Breaking Oral Presentation By: PR Newswire Mar. 30, 2009 08:01 AM // GENEVA, Switzerland, March 30 /PRNewswire/ — Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the American Academy of Neurology (AAN) has accepted a late-breaking abstract regarding cladribine [...]

  • Breast Feeding Works Miracles for Both Baby and Mother with MS

    AAN 2009: Breast-Feeding May Reduce Multiple Sclerosis Relapses Allison Gandey February 23, 2009 — Women who have multiple sclerosis (MS) may reduce their risk for relapse after pregnancy if they breast-feed, a new study suggests. “Our findings call into question the benefit of choosing not to breast-feed or stopping breast-feeding early in order to start [...]

TAG / CLOUD

AAN, alemtuzumab, Avonex, Bayer, Betaseron, Biogen, BioMS Medical Corp, CCSVI, CIS, Cladribine, CLARITY, cognitive dysfunction, Copaxone, daclizumab, dirucotide, discovery, EAE, ECTRIMS, Elan, Fampridine-SR, FDA, FDA fast track status, fingolimod, FTY-720, Gilenia, interferons, laquinimod, Marijuana, Merck, Merck/Serono, Novartis, Oral MS Therapies, Phase III, PML, Rebif, remyelination, RRMS, side effects, smoking, SPMS, stem cells, Teriflunomide, Teva, therapy, Tysabri

Archives



Follow me on Twitter
Fave this on Technorati


Bookmark and Share


Wordpress Engine. Upstart Theme. Better Project.